Zanco Journal of Medical Sciences
Skip Navigation Links
Available Issues
Editorial Board
Information for Authors
Review Process
Links and Contacts
  Zanko J Med Sci:  Apr. 2017; 21 (1): 1629-1635

Immunoexpression of P53 protein in trophoblastic diseases

Sanarya M. Ali*, Nadya Y. Ahmedi**, Tenya T. Abdulhameed**, Tara M. Shalal**

* Department of Pathology, Ministry of Health, Erbil, Iraq.

** Department of Pathology, College of Medicine, Hawler Medical University, Erbil, Iraq.


Background and objective: Trophoblastic diseases constitute a spectrum of tumors and tumor- like conditions characterized by proliferation of pregnancy associated trophoblastic tissue of progressive malignant potential. This study aimed to assess the value of p53 protein immunoexpression in the diagnosis of hydatidiform molar pregnancy and the differential diagnosis of its subtypes (complete and partial) from abortions.

Methods: A cross-sectional study of tissue sections from 68 formalin-fixed, paraffin- embedded specimens of products of conception, including 1st trimester abortion (n=15), partial hydatidiform mole PHM (n=24), complete hydatidiform CHM (n=24) and full term placenta (n=5), all were examined at the Histopathology Department of Maternity Teaching Hospital in Erbil, Iraq during the period of Jan.2013-Jun.2013. Immunohistochemistry was performed using p53 antibody and the standard streptavidin-biotin immunoperoxidase method. The labeling index (number of positive nuclei/total number of nuclei) for villous cytotrophoblasts, syncytiotrophoblasts and stromal cells were evaluated separately. Statistical analysis was carried out by one way ANOVA and Fisher’s exact tests, statistical significance was determined at P ≤0.05.

Results: All villous trophoblastic lesions showed higher p53 immunoexpression in all villous components especially cytotrophoblasts, being the highest in complete hydatidiform mole (>50%) and partial hydatidiform mole (>20%). A statistically significant difference was found in immunoexpressins of p53 that was useful in separating abortion from complete hydatidiformmole, P <0.001, and partial hydatidiform mole, P <0.0002. It was also useful in separating between the complete hydatidiform mole and partial hydatidiform mole (P <0.001).

Conclusion: p53 immunoexpression was valuable in differentiation between molar and non molar pregnancies and between subtypes of molar pregnancies.

Keywords: Hydatidiform Mole; Abortion; p53; Immunohistochemistry.


1. Hextan YS, Michael J, Ross S, Yang X, François G, Sekharan PK, et al. Update on the diagnosis and management of gestationaltrophoblastic disease. IJGO 2015; 132:123–6.

2. Clement PB, Young RH. Trophoblastic lesions, miscellaneous primary uterine neoplasms, hematopoietic neoplasms, and metastatic neoplasms to the uterus. In: Clement PB, Young RH, editors. Atlas of Gynecologic Surgical Pathology. 3rd ed. Oxford: Saunders, Elsevier Inc; 2014. p. 284–310.

3. Merchant SH, Amin MB, Viswanatha DS, Malhotra RK, Moehlenkamp C, Joste NE. P57kip2 Immunohistochemistry in early molar pregnancies: Emphasis on its complementary role in the differential diagnosis of hydropicabortuses. Human Pathol 2005; 36:180–6.

4. Fukunaga M, Katabuchi H, Nagasaka T, Mikami Y, Minamiguchi S, Lage JM. Interobserver and intraobserver variability in the diagnosis of hydatidiform mole. Am J Surg Pathol 2005; 29:942–7.

5. Etebary M, JahanzadI ,Mohagheghi MA, Azizi E. Immunohistocmechemical analysis of p53 and its correlation to the other prognositic factors in breast cancer. Acta Medica Iranica 2002; 40(2):88–94.

6. Srendini ST, Zerbin MCN, Latorre MR, Alves VAF. p53 as aprognostic factor in adrenocortical tumors of adults and children. Braz J Med Biol Res 2003; 36:23–7.

7. Yazaki-Sun S, Daher S, de Souza Ishigai MM, Alves MT, Mantovani TM, Mattar R. Correlation of c-erbB-2 oncogene and p53 tumor suppressor gene with malignant transformation of hydatidiform mole. J Obstet Gynaecol Res 2006; 32:265–72.

8. Hsu SM, Raine L, Fanger H. Use of avidin-peroxidase coplex (ABO) in immunoperoxidasetechniques:a comparison between ABC and unlabeled antibody (PAP) procedures. J Histochem Cytochem 1981; 29:577–80.

9. Erfanan M, Sharifi N, Omidi AA. p63 and Ki-67 expression in trophoblastic disease and spontaneous abortion; JRMS 2009; 14(6):375–84.

10. Hasanzadeh M, Sharifi N, Esmaieli H, Daloee MS, Tabari A. Immunohistochemical expression of the proliferative marker Ki67 in hydatidiform moles and its diagnostic value in the progression to gestational trophoblastic neoplasoia. J Obstet Gynaecol 2013; 39(2):572–7.

11. Sebire NJ, Rees H. Diagnosis of gestational trophoblastic disease in early pregnancy. Current Diagnostic Pathology 2002; 8(6):430–40.

12. Nizam K, Haidar G, Memon N, Haidar A. Gestational Trophoblastic Disease: Experience at Nawabshah Hospital. JAyub Med Coll 2009; 21:67–9.

13. Chen YX, Shen DH, Gu YQ, Zhong PP, Xie JL, Song QJ, et al. Immunohistochemistry of p57 and p53 protein in differential diagnosis of hydropic abortion, partial and complete hydatidiform mole. Zhonghua Bing Li XueZaZhi 2011; 40(10):694–700.

14. Ichikawa N, Zhai YL, ShiozawaT, Toki T, Nouguchi H, Nikaido T, et al. Immunohistochemical Analysis Of Cell Cycle Regulatroy Gene Products in normal Trophoblast and Placental site Trophoblastic Tumor. Int J Gynaecol Pathol 1998; 17(3):235–40.

15. Petigant P,Laurini R, Goffin F, Bruchim I, Bischof P. Expression of matrix metalloproteinase-2 and mutant p53 is increased in hydatiform mole as compared with normal placenta. Int J Gynecol Cancer 2006; 16(4):1679–84.

16. Al-Bozom IA. p53 and bcl2 oncoprotein expression in placentas with hydropic changes and partial and complete moles. APMIS 2000; 108:756–60.

17. Halperin R, Peller S, Sandbank J, Bukovsky I, Schneider D. Expression of p53 Gene and Apoptosis in Gestational Trophoblastic Disease. Placenta 2000; 21:58–62.

18. Hussein MR. Analysis of p53, Bcl2 and epidermal growth factor receptor protein expression in the partial and complete hydatiform moles. Exp Mol Pathol 2009; 87(1):63–9.

19. Kale A, Soylemez F, EnsariA. Expression of proliferation marker (ki-67, proliferating cell nuclear antigen, and silver staining nuclear organizer regions) and of p53 tumor protein in gestational trophoblastic disease. Am J Surg Pathol 2001; 33:176–85.

20. UzunlarAK, YilmazF, Bayhan G, Akkus Z. Expression of p53, proliferation cell nuclear antigen, and ki-67 in gestational trophoblastic disease. Eur J Gynaecol Oncol 2002; 23:79–83.

21. Chen Y, Shen D, Gu Y, Zhong P, Xie J, Song Q. The Diagnostic value of Ki-67, p53, and p63 in distinguishing partial HM from hydropic abortion. Wien Klin Wochenschr 2012: 124:184–7.

22. Shih IM, Kurman RJ. P63 expression is useful in distinction of epithelioid trophoblastic and placental site trophoblastic tumors by profiling trophoblastic subpopulations. Am J Surg Pathol 2004; 28(9):1177–83.

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.